 | |
| Clinical data | |
|---|---|
| Other names | 2-Bromo-2C-B; 2,5-Dimethoxy-4,6-dibromophenethylamine; 2,4-Dibromo-3,6-dimethoxyphenethylamine |
| Routes of administration | Oral [1] |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | 6–8 hours [1] |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C10H13Br2NO2 |
| Molar mass | 339.027 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
2C-DB, also known as 2,5-dimethoxy-4,6-dibromophenethylamine or as 6-bromo-2C-B, is a psychedelic drug of the phenethylamine and 2C families related to 2C-B. [1] It is the 6-bromo derivative of 2C-B and the 4,6-dibromo derivative of 2,5-dimethoxyphenethylamine (2C-H). [1] The drug has a dose range of 20 to 35 mg orally and a duration of 6 to 8 hours. [1] For comparison, 2C-B has a dose of 12 to 24 mg and a duration of 4 to 8 hours. [1] 2C-DB is described as having largely the same effects as 2C-B. [1] However, it is said that the drug may have somewhat greater visual effects than 2C-B. [1] 2C-DB was synthesized and tested by P. Rausch in the 1990s or 2000s. [1] [2] It was described in the scientific literature by Daniel Trachsel in 2013, who cited personal communication with Rausch as the source for the information. [1]
